Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Shifting R&D Funds To Early-Stage Compound Research And Licensing

Executive Summary

Wyeth is moving R&D spend from Phase III projects to discovery and early stage programs in an effort to continue meeting its goal of submitting two NDAs for new molecular entities per year, R&D President Robert Ruffolo said

You may also be interested in...



Wyeth’s R&D Strategy: Spoonfuls Of Enrollment With A Dash Of Outsourcing

Wyeth research and development efforts are focusing on global patient enrollment as a key method to accelerate the drug development process

Wyeth’s R&D Strategy: Spoonfuls Of Enrollment With A Dash Of Outsourcing

Wyeth research and development efforts are focusing on global patient enrollment as a key method to accelerate the drug development process

Enhanced Phase II Efforts Paying Dividends, But At A Price, Pfizer Exec Says

Expanded approaches to Phase II development have reduced Phase III attrition rates, but in doing so, have also created a new set of challenges for pharmaceutical companies, according to Pfizer Senior VP-Science & Technology Peter Corr

Related Content

Topics

UsernamePublicRestriction

Register

PS046395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel